Stem cells for transplantation and manufacturing method therefor

Abstract

It is intended to provide MSCs for transplantation that have an improved post-transplantation cell survival rate and engraftment rate and are highly safe with fewer adverse reactions, and a method for conveniently producing MSCs for transplantation having a high cell survival rate and engraftment rate. As means therefor, the present invention provides a stem cell for transplantation comprising an MSC capable of overexpressing IL-10.

1 . A stem cell for transplantation comprising a mesenchymal stem cell capable of overexpressing interleukin-10 (IL-10). 
     
     
         2 . The stem cell for transplantation according to  claim 1 , wherein the overexpression of IL-10 is caused by an exogenous IL-10 expression system. 
     
     
         3 . The stem cell for transplantation according to  claim 2 , wherein the IL-10 expression system is a plasmid vector or a virus vector. 
     
     
         4 . The stem cell for transplantation according to  claim 1 , wherein the stem cell is intended for the regeneration of mesenchymal connective tissue, the central nervous system, or the liver. 
     
     
         5 . A method for producing a stem cell for transplantation, comprising the step of introducing an IL-10 expression system capable of overexpressing IL-10 to a mesenchymal stem cell. 
     
     
         6 . The method for producing a stem cell for transplantation according to  claim 5 , wherein the IL-10 expression system is a plasmid vector or a virus vector. 
     
     
         7 . An agent for enhancing engraftment of mesenchymal stem cell, comprising an IL-10 expression system capable of overexpressing IL-10 as an active ingredient. 
     
     
         8 . The agent for enhancing engraftment of mesenchymal stem cell according to  claim 7 , wherein the IL-10 expression system is a plasmid vector or a virus vector. 
     
     
         9 . A method for inducing acquired immunological tolerance, comprising:
 a first step of administering, within a period from 2 to 14 days before introduction of an immunogen, a mesenchymal stem cell and an immunogen having the same immunogenicity as that of said immunogen, or a part thereof to a recipient individual at least once; and   a second step of administering a mesenchymal stem cell to the recipient individual on the day before or the very day of the introduction of the immunogen.   
     
     
         10 . The method according to  claim 9 , wherein the mesenchymal stem cell is a stem cell for transplantation capable of overexpressing interleukin-10 (IL-10). 
     
     
         11 . The method according to  claim 9 , wherein the immunogen is a virus, a cell, a tissue, or an organ. 
     
     
         12 . The stem cell for transplantation according to  claim 2 , wherein the stem cell is intended for the regeneration of mesenchymal connective tissue, the central nervous system, or the liver. 
     
     
         13 . The stem cell for transplantation according to  claim 3 , wherein the stem cell is intended for the regeneration of mesenchymal connective tissue, the central nervous system, or the liver. 
     
     
         14 . The method according to  claim 9 , wherein the mesenchymal stem cell is a stem cell for transplantation and capable of overexpressing interleukin-10 (IL-10), wherein the overexpression of IL-10 is caused by an exogenous IL-10 expression system. 
     
     
         15 . The method according to  claim 14 , wherein the exogenous IL-10 expression system is a plasmid vector or a virus vector. 
     
     
         16 . The method according to  claim 9 , wherein the mesenchymal stem cell is a stem cell for transplantation, wherein the mesenchymal stem cell is capable of overexpressing interleukin-10 (IL-10) and is intended for the regeneration of mesenchymal connective tissue, the central nervous system, or the liver. 
     
     
         17 . The method according to  claim 10 , wherein the immunogen is a virus, a cell, a tissue, or an organ.